Biogen Idec GmbH


    • Company type:
      • Manufacturer
    • Year founded:
    • 1978
    • Employees (at the site):
    • 200
    • Turnover range:
    • 10m - <50m EUR
    • Products/services:
    • Autoimmune Diseases; Research, Production and Distribution of Drugs

    • Core competencies:
    • Biogen Idec, Inc., winner of the 1998 U.S. National Medal of Technology, is a biopharmaceutical company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Headquartered in Cambridge, MA, the Company's revenues are generated from U.S. and European sales of AVONEX® (Interferon beta-1a) for treatment of relapsing forms of multiple sclerosis, and from the worldwide sales by licensees of a number of products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen Idec's research and development activities are focused on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases and in developmental biology and gene therapy.

    • Language skills:
    • German
    • Key Tech / section:
      • Biotechnology: Molecular diagnostics for humans
      • Biotechnology: Therapeutic drug development
    • Certification:
    • not available

    • Sales markets - target industries:
    • not available
    • Sales markets - target countries:
    • not available
    • Cooperation offers:
    • not available
    • Contact person:
    • David Allsop (Mr.)
      - Management

      Bernd Zimmermann (Mr.)
      - Management

      Boudewijn van Bochove (Mr.)
      - Management